Study: Individuals with Depression More Likely to Use Cannabis

Cannabis is on the rise in the United States, especially among those suffering from depression. According to a study published in the journal Addiction, individuals with depression were more likely than those without depression to use cannabis.

“Depression is not generally a condition for which medicinal cannabis is prescribed, and it is not clear why recreational use would occur disproportionately among those with depression,” said study co-author Dr. Renee Goodwin in a statement. “It is conceivable that cannabis may be increasingly used in an attempt to self-medicate depression in states where it is legal for recreational use.”

Though there is not yet a scientific consensus on whether cannabis may or may not help treat depression, one study conducted by the University of British Columbia did find that patients with post-traumatic stress disorder were less likely to suffer from depression if they used medical cannabis.

For this current study, researchers surveyed 728,691 people over the age of 12 between the years 2005 and 2017.  Respondents were tasked with self-reported any, daily, and non‐daily past‐30‐day cannabis use and perceived great risk associated with regular cannabis use.

They found that slightly more than twice as many individuals with depression (18.94% in 2017) used cannabis than those without depression (8.67% in 2017). Adults with depression between the ages of 18 and 35 were more likely to use cannabis, with approximately one-third reporting cannabis use. Overall, cannabis use amongst both groups rose between 2005 and 2017.

Researchers also found that people with depression were significantly more likely to view cannabis as low risk when compared to those without depression.

“The prevalence of cannabis use among those with depression who perceived no risk associated with regular use was much higher than among those who perceived significant risk associated with use — 39 percent versus 1.6 percent, respectively,” added Goodwin. “With increasing legalization in the U.S., previous studies have shown that perception of risk associated with use is declining overall. The results of this study show that this decline is even more rapid among this vulnerable population: those with depression.”

William Sumner

William Sumner is a freelance writer specializing in the legal cannabis industry. You can follow William on Twitter @W_Sumner or on Medium.

One comment

  • Allan Poshel

    January 18, 2021 at 4:04 pm

    Among all sites this platform definitely provides the best online therapy. I saw amwell review a few months ago, but I’ve already managed to get attached to it. This is one of the few sites that has an incredibly large range of services. Everyone can find what they need. Whether it’s psychotherapy or even cardiac services. The cost of this service is lower than going to the doctor’s office, and the ease of use is incomparable. I am incredibly glad that there are sites like this, because how much time I save on this. I recommend it 100%)))


Leave a Reply

Your email address will not be published. Required fields are marked *

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.


We respect your privacy. See our privacy policy.

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 11 hours

Researchers Seek to Remove ‘Trip’ as Popularity of Psychedelic Treatments Grows

@GreenMarketRpt – 14 hours

The Weekly Stash Video September 30, 2022

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.


We respect your privacy. See our privacy policy.